The data support azetukalner as a best-in-class therapy for treatment-resistant epilepsy, with strong efficacy, long-term seizure freedom, and patient-friendly dosing. With NDA submission expected in Q3 2026, XENE is a compelling near-term regulatory catalyst play. Traders should monitor for FDA feedback and potential partnership interest.
XENE drugs
XENE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $57.09entry
- T+1 · 7mo ago −1.21%α −0.56% · $56.40
- T+5 · 7mo ago −4.96%α −5.87% · $54.26
- T+20 · 6mo ago −5.92%α −10.12% · $53.71
- T+60 · 4mo ago +18.60%α +11.82% · $67.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset seizures at the AAN 2026 meeting, showing statistically significant and durable seizure reduction, with nearly 40% of long-term patients achieving at least 12 months of seizure freedom. The company plans to submit an NDA to the FDA in Q3 2026.
Key Facts
- Azetukalner 25 mg achieved a 53.2% reduction in monthly seizure frequency vs. 10.4% for placebo (p<0.0001) in the Phase 3 X-TOLE2 trial.
- Long-term data from the X-TOLE OLE study show 38.2% of patients treated for ≥48 months achieved at least 12 months of seizure freedom.
- Azetukalner demonstrated consistent safety with low rates of serious adverse events (5.6% in 25 mg group vs. 2.4% placebo).
- Xenon plans to submit an NDA for azetukalner in epilepsy to the FDA in Q3 2026.
Financial Impact
High commercial potential in a $5B market; azetukalner could capture significant share given best-in-class efficacy and no-titration advantage.
Risk Factors
- Regulatory delay or rejection of NDA submission
- Competition from established ASMs and emerging therapies
- Potential safety signals in larger patient populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276673 |
Track record
19 reports on XENE
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.28% at T+60 after the Mar 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers